Standards; Chiral Molecules; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.